Obesity Market is Expected to Witness Significant Growth by 2036 Due to Advancements in GLP-1 Therapies and Expanding Treatment Accessibility | DelveInsight

The obesity market is experiencing substantial transformation driven by the rising global obesity burden, growing awareness regarding obesity as a chronic disease, increasing adoption of GLP-1 receptor agonists, and the emergence of next-generation metabolic therapies. The anticipated launch of innovative therapies such as Retatrutide, Survodutide, CagriSema, VK2735, and Amycretin is expected to further accelerate market growth across the 7MM during the forecast period.
DelveInsight, a leading business consulting and market research company, has released its latest report, "Obesity Market Insight, Epidemiology, and Market Forecast - 2036," providing comprehensive insights into obesity epidemiology, treatment practices, marketed and emerging therapies, and market dynamics across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Obesity Market Report

*
The obesity market in the 7MM is projected to grow substantially by 2036 due to expanding use of incretin-based therapies and increasing treatment uptake.

*
DelveInsight estimates that the obesity market size in the 7MM was approximately USD 16 billion in 2025 and is anticipated to increase significantly through 2036.

*
According to DelveInsight's analysis, the United States represented approximately 60% of the total prevalent obesity cases across the 7MM in 2025.

*
In the US, around 5.5 million children aged 5-19 years were living with obesity in 2025.

*
Germany reported approximately 18 million prevalent obesity cases in 2025, representing the highest disease burden among EU4 and the UK.

*
Existing marketed therapies include WEGOVY, ZEPBOUND, SAXENDA, CONTRAVE/MYSIMBA, and QYSMIA.

*
WEGOVY and ZEPBOUND continue to dominate the obesity treatment landscape owing to their strong efficacy profiles and expanding global approvals.

*
In April 2026, Eli Lilly announced that the US FDA approved FOUNDAYO (orforglipron) for adults with obesity or overweight and weight-related comorbidities.

*
Emerging therapies including Retatrutide, Survodutide, CagriSema, VK2735, Amycretin, MariTide, CT-388, and Pemvidutide are expected to reshape future obesity management.

*
The obesity pipeline is highly competitive, with several therapies in Phase III clinical development demonstrating promising efficacy and metabolic benefits.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Key Factors Driving the Obesity Market

Increasing Global Obesity Burden

Rising prevalence of obesity among adults and children continues to fuel demand for effective long-term treatment strategies. Sedentary lifestyles, dietary changes, and metabolic disorders are contributing significantly to disease growth worldwide.

Growing Adoption of GLP-1 and Dual/Triple Agonist Therapies

The success of GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Therapies targeting GLP-1, GIP, and glucagon receptors are delivering unprecedented weight reduction outcomes compared to older therapies.

Expanding Awareness of Obesity as a Chronic Disease

Healthcare systems and medical societies increasingly recognize obesity as a chronic metabolic disease associated with major comorbidities including cardiovascular disease, diabetes, hypertension, and sleep apnea, driving greater treatment adoption.

Advancements in Precision and Combination Therapies

Emerging personalized approaches and multi-target metabolic therapies are improving efficacy, metabolic control, and long-term treatment outcomes while expanding therapeutic options for patients.

Obesity Competitive Landscape

*
The obesity market is currently dominated by incretin-based therapies such as WEGOVY (semaglutide) and ZEPBOUND (tirzepatide), which have demonstrated substantial weight loss efficacy and growing physician adoption globally.

Key Marketed Therapies

*
WEGOVY (semaglutide) - Novo Nordisk

*
ZEPBOUND (tirzepatide) - Eli Lilly

*
SAXENDA (liraglutide) - Novo Nordisk

*
CONTRAVE/MYSIMBA (naltrexone-bupropion)

*
QYSMIA (phentermine-topiramate)

Emerging Therapies in Development

*
Survodutide (BI 456906) - Boehringer Ingelheim

*
Retatrutide - Eli Lilly

*
CagriSema - Novo Nordisk

*
VK2735 - Viking Therapeutics

*
Amycretin - Novo Nordisk

*
Pemvidutide (ALT-801) - Altimmune

*
MariTide - Amgen

*
CT-388 - Carmot Therapeutics/Roche

*
FOUNDAYO (orforglipron) - Eli Lilly

*
RGT-075 - Regor Therapeutics

These emerging therapies are expected to intensify competition and expand treatment accessibility over the forecast period.

Discover more about therapies set to grab major Obesity Market share @ Obesity Market Landscape [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Obesity Market

*
In April 2026, Eli Lilly announced US FDA approval of FOUNDAYO (orforglipron) for obesity and overweight patients with weight-related comorbidities.

*
In January 2026, Novo Nordisk announced broad US availability of oral WEGOVY, the first oral GLP-1 therapy approved for weight loss.

*
In December 2025, Novo Nordisk submitted an NDA to the US FDA for CagriSema for chronic weight management.

*
In September 2025, Regeneron reported positive interim Phase II COURAGE trial data evaluating semaglutide combinations for obesity treatment.

*
Orforglipron demonstrated significant weight loss and cardiometabolic benefits in the ATTAIN-1 study published in The New England Journal of Medicine.

What is Obesity?

Obesity is a chronic, multifactorial, non-communicable disease characterized by excessive adiposity or body fat accumulation that adversely impacts health. It results primarily from an imbalance between energy intake and energy expenditure, influenced by environmental, psychosocial, metabolic, and genetic factors.

Diagnosis is generally based on Body Mass Index (BMI), calculated as weight in kilograms divided by height squared in meters. Obesity is associated with increased risks of cardiovascular disease, diabetes, hypertension, sleep apnea, metabolic syndrome, and several other chronic disorders.

Obesity Epidemiology Segmentation

The obesity epidemiology section in the report provides historical and forecasted data across the 7MM from 2022-2036, segmented into:

*
Total Prevalent Cases of Obesity

*
Adult Obesity Cases

*
Childhood Obesity Cases

*
Total Treated Cases of Obesity

*
Country-specific Obesity Burden

*
Patients Seeking Treatment

*
Therapy-specific Treated Population

Scope of the Obesity Market Report

*
Comprehensive overview of obesity pathophysiology and treatment landscape

*
Historical and forecasted obesity market size analysis

*
Epidemiology segmentation across the 7MM

*
Assessment of marketed and emerging therapies

*
Competitive landscape and pipeline analysis

*
Market drivers, barriers, SWOT, and unmet needs

*
KOL perspectives and analyst insights

*
Market access and reimbursement analysis

To know more about Obesity companies working in the treatment market, visit @ Obesity Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Key Insights

*
Report Introduction

*
Executive Summary

*
Key Events

*
Epidemiology and Market Forecast Methodology

*
Obesity Market Overview at a Glance

*
Disease Background and Overview

*
Diagnosis

*
Treatment and Management

*
Epidemiology and Patient Population

*
Patient Journey

*
Marketed Therapies

*
Emerging Therapies

*
Obesity Market Analysis

*
KOL Views

*
SWOT Analysis

*
Unmet Needs

*
Market Access and Reimbursement

*
Appendix

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading business consulting and market research company focused exclusively on life sciences. The company provides comprehensive market intelligence, epidemiology forecasting, pipeline analysis, and strategic consulting services to pharmaceutical and biotechnology companies worldwide.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=obesity-market-is-expected-to-witness-significant-growth-by-2036-due-to-advancements-in-glp1-therapies-and-expanding-treatment-accessibility-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.